Life sciences
Grant writers who speak your science
Why life sciences applications fail
Strong science, weak proposal. The most common reasons we see: aims that aren't hypothesis-driven, no clear go/no-go milestones, missing power calculations, a regulatory pathway that assessors can't follow, and a commercialisation plan written as an afterthought.
We fix all five, in your own scientific voice, backed by writers who have sat on the research side of the bench.
Where we work
Therapeutics & drug discovery
Small molecule, biologics and cell & gene programmes. Target validation through to clinical translation.
Diagnostics & devices
Assay development, point-of-care platforms, imaging and UKCA/MHRA device pathways.
Digital health & AI
Clinical decision support, remote monitoring and AI/ML models with a credible NHS validation plan.
Research tools & bioprocessing
Instruments, reagents, organoids, lab automation and manufacturing scale-up.
Programmes we target
Innovate UK Biomedical Catalyst
Feasibility and industrial research awards for early-stage life science innovation, typically 70% intervention for SMEs.
MRC & NIHR
Translational and applied health research funding, reviewed by clinical and biomedical panels with strong NHS relevance.
EIT Health & Horizon Europe
European co-funding for health innovation moving from validation into adoption, plus blended EIC Accelerator finance for scale-ups.
The Innovate UK route, stage by stage
Biomedical and health technology is one of the strongest-performing areas for Innovate UK grant competitions, and many life sciences platforms score better here than through a purely academic route. Feasibility, industrial research and late-stage scale-up funding each ask for a different kind of evidence.
Feasibility studies
Up to 70% intervention
Prove the core scientific or technical hypothesis before committing to a full development programme.
Industrial research
Up to 45% intervention
Develop and validate the technology against a defined clinical or commercial use case.
EIC Accelerator
Up to €2.5m + equity
Blended grant and equity finance for later-stage scale-ups ready for European markets.
Let's fund your science
Book a free consultation with a grant writer who understands your therapeutic area or device pathway.